InterCure to Participate in Cowen 5th Annual Cannabis Conference
Get Alerts INCR Hot Sheet
Join SI Premium – FREE
Mr. Rabinovitch is one of the global cannabis senior executives to participate
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 08, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will participate in Cowen 5th Annual Cannabis Conference, taking place December 8th, 2022.
Mr. Rabinovitch will take part in the industry leaders panel on Thursday, December 8th, 2022 at 9:30 AM EST, and will be available for 1 on 1 sessions by appointment only.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The King Center and Divine Nine Launch Historic Fundraising Campaign to Preserve Critical History and Amplify Nonviolence365® Ahead of King100
- Glitter Bug Gold Buyers Announces New Gold Seller Transparency Standard Across Orange County Locations
- Karsan Autonomous e-ATAK Begins Passenger Service at the World-Famous Efteling Theme Park
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share